Adaptive Biotechnologies’ Chief Scientific Officer, Harlan S. Robins, reported preset stock sales under a Rule 10b5-1 trading plan. On February 2, 2026, he sold 34,668 shares of common stock at a weighted average price of $18.60, followed by a sale of 8,120 shares on February 3, 2026 at a weighted average price of $19.00.
The filing notes these trades were executed under a trading plan adopted on August 11, 2025, and that each reported price reflects multiple trades within stated ranges. After these transactions, Robins beneficially owned 1,179,524 shares of Adaptive Biotechnologies common stock directly.
Adaptive Biotechnologies CEO and Chairman Chad M. Robins reported a planned stock sale. On February 2, 2026, he sold 124,998 shares of Common Stock at a weighted average price of $18.44 per share, in transactions executed under a Rule 10b5-1 trading plan adopted on August 11, 2025.
After this sale, Robins beneficially owned 2,459,245 shares of Adaptive Biotechnologies Common Stock in direct form.
A shareholder of ADPT, identified as Harlan Robins, filed a notice to sell 8,120 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of 150,220, on or about 02/03/2026 on the NASD exchange.
The shares to be sold were acquired on 03/06/2023 as compensation in the form of restricted stock units from the issuer. Over the prior three months, the same seller reported multiple open-market sales of common stock, with individual transactions ranging up to 27,212 shares and gross proceeds such as 506,428.93.
ADPT insider Harlan Robins has filed a notice of proposed common stock sales under Rule 144. The filing covers the planned sale of 34,668 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $637,544.52, listed for trading on NASD. These shares are part of a broader compensation history where Robins acquired 17,220 restricted stock units on 03/04/2022, 17,170 on 03/04/2021, and 278 on 03/06/2023, all from the issuer as compensation. In the past three months, he has already sold several blocks of common stock, including 10,000 shares on 11/10/2025 for $148,213, 27,212 shares on 12/03/2025 for $506,428.93, 10,000 shares on 12/04/2025 for $166,125, and 10,000 shares on 01/06/2026 for $164,412.
Chad M. Robins filed a Rule 144 notice to sell 124,998 shares of common stock, with an aggregate market value of $2,298,713.22, through Goldman Sachs & Co. LLC on or about 02/02/2026 on the NASD exchange.
The shares include stock acquired as performance-based compensation on 03/04/2022 (119,419 shares) and earlier founder’s shares from 09/01/2009 (5,579 shares). The issuer had 152,665,188 shares outstanding. Robins has already completed multiple common stock sales in recent months between 11/10/2025 and 01/05/2026.
BlackRock, Inc. has filed an amended Schedule 13G showing a significant institutional position in Adaptive Biotechnologies Corp common stock. BlackRock reports beneficial ownership of 11,992,448 shares, representing 7.9% of the outstanding common stock. It has sole power to vote 11,764,835 of these shares and sole power to dispose of all 11,992,448 shares, with no shared voting or dispositive power.
BlackRock classifies itself as a holding company and states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Adaptive Biotechnologies. Various underlying clients and accounts have rights to dividends or sale proceeds, but no single person has more than five percent of the issuer’s total outstanding common shares.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported option exercises and a share sale in company stock. On January 12, 2026, Lo exercised several stock options, acquiring 36,650 shares at $7.80, 7,723 shares at $12.14, 21,002 shares at $8.46, and 14,215 shares at $3.99 per share. The same day, Lo sold 79,590 shares of common stock at $17.73 per share. After these transactions, Lo directly owned 315,978 shares of common stock and indirectly owned 2,500 shares through a spouse. The filing notes that these transactions were made under a Rule 10b5-1 trading plan adopted on September 15, 2025, and that the reported options are fully or time-vested according to their respective vesting schedules.
Adaptive Biotechnologies Corp Chief Financial Officer Kyle Piskel reported an option exercise and share sale in company stock. On January 12, 2026, he exercised stock options for 4,290 shares of common stock at an exercise price of $12.14 per share, receiving 4,290 shares.
On the same date, he sold 4,290 shares of common stock at a price of $18 per share, leaving him with 216,637 shares of common stock held directly after the transactions. The filing notes these trades were carried out under a Rule 10b5-1 trading plan adopted on August 28, 2025. Following the exercise, 4,291 stock options remained beneficially owned.
A holder of ADPT common stock has filed a notice of proposed sale under Rule 144 for 64,293 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an aggregate market value of 1,013,257.68. These shares were acquired on 01/12/2026 via a cash exercise of stock options from the issuer, with payment also made on that date.
The notice also lists prior Rule 10b5-1 sales for Francis Lo over the past three months, including a sale of 113,890 common shares on 12/15/2025 for gross proceeds of 1,773,381.19, along with additional smaller sales on 12/22/2025 and 01/02/2026. By signing, the seller represents not knowing any undisclosed material adverse information about the issuer.
Adaptive Biotechnologies security holder files a Form 144 notice to sell common stock. The filing covers a proposed sale of 11,081 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $174,636.56 and an approximate sale date of 01/12/2026.
The shares to be sold were acquired through stock option exercises, including 8,581 shares exercised for cash on 01/12/2026 and 2,500 shares previously exercised for cash on 03/14/2025. Over the past three months, the person for whose account the securities are to be sold has already sold common shares, including 162,820 shares on 11/28/2025 for gross proceeds of $3,174,534.10 and 238 shares on 11/17/2025 for $3,343.90, with one entry identified as 10b5-1 sales.